1. Johnson Fistel investigates DexCom for potential fiduciary breaches. 2. DexCom issued misleading statements about its market strategy since April 2023. 3. Shares dropped over 40.6% following corrective disclosures in mid-2024. 4. Current stockholders are advised to discuss legal rights. 5. Investigation follows public disclosures of lower-than-expected growth.